CCT244747 is a potent, orally bioavailable and highly selective CHK1 inhibitor, with an IC 50 of 7.7 nM; CCT244747 also abrogates G2 checkpoint with an IC 50 of 29 nM.
Storage Temp
Store at -20°C
Shipped In
Ice chest + Ice pads
Product Description
CCT244747 is a potent, orally bioavailable and highly selective CHK1 inhibitor, with an IC 50 of 7.7 nM; CCT244747 also abrogates G2 checkpoint with an IC 50 of 29 nM.
In Vitro
CCT244747 poorly inhibits CHK2 (IC 50 >10 μM) and CDK1 (IC 50 >10 μM). CCT244747 has potent activities against CHK1, RSK1, RSK2, AMPK, BRSK1, IRAK1,and TrkA, with >80% inhibition. CCT244747 (10 μM) exhibits <25% inhibition of the other ion channels including hNav1.5, hKv4.3/hKChIP2, hCav1.2, hKv1.5, hKCNQ1/hminK, hHCN4. CCT244747 inhibits FLT3 with an IC 50 of 600 nM. CCT244747 (0.5 μM) overcomes genotoxic-induced S and G2 cell cycle arrest in human colon cancer cell lines. CCT244747 inhibits cellular CHK1 function with IC 50 s ranging from 29 nM to 170 nM for cellular G2 checkpoint abrogation (MIA, mitosis induction assay) in HT29, SW620, MiaPaCa-2, and Calu6 cell lines; the GI 50 s are between 0.33 and 3μM. CCT244747 (0.3 μM) inhibits SN38 and gemcitabine-induced CHK1 activity in HT29 and SW620 colon cancer cell lines and this correlates with abrogation of cell cycle arrest, induction of DNA damage and apoptosis. CCT244747 (0.5-2.0 μM) increases the sensitivity of bladder and head and neck cancer cell lines (T24, RT112 and Cal27) to radiation. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
CCT244747 (100 mg/kg po, qd7d) significantly reduces tumor burden in human tumor xenografts. CCT244747 (100-300 mg/kg, po) inhibits gemcitabine-induced pS296 CHK1 for up to 24 h in HT29 colon tumor xenografts . CCT244747 (75 mg/kg, p.o.) in combination with gemcitabine has potent antitumor effects in HT29 colon tumor xenografts and Calu6 human lung cancer xenografts. CCT244747 (150 mg/kg p.o.) also shows antitumor activities with irinotecan in SW620 human colon tumor xenografts. CCT244747 (100 mg/kg, p.o.) exhibits radiosensitization activity in Cal27 xenografts. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
